^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    RG6540

    i
    Other names: RG6540, RG-6540, RG 6540, P-CD19CD20-ALLO1, PCD19CD20ALLO1, P CD19CD20 ALLO1
    Associations

    News

    Trials
    Company:
    Poseida Therap, Roche
    Drug class:
    CD19-targeted CAR-T immunotherapy, CD20-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    7ms
    P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies (clinicaltrials.gov)
    P1, N=100, Recruiting, Poseida Therapeutics, Inc. | Initiation date: Jan 2024 --> Apr 2024
    Trial initiation date • CAR T-Cell Therapy
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    CD20 positive
    |
    RG6540 • rimiducid (AP1903)
    10ms
    P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies (clinicaltrials.gov)
    P1, N=100, Recruiting, Poseida Therapeutics, Inc. | Not yet recruiting --> Recruiting | N=70 --> 100
    Enrollment open • Enrollment change • CAR T-Cell Therapy
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    CD20 positive
    |
    RG6540 • rimiducid (AP1903)
    1year
    P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies (clinicaltrials.gov)
    P1, N=70, Not yet recruiting, Poseida Therapeutics, Inc.
    New P1 trial • CAR T-Cell Therapy
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    CD20 positive
    |
    RG6540 • rimiducid (AP1903)